心臟病学和神经病学市场的IVD - 按产品类型（仪器、试剂、试剂盒和消耗品、软体和服务）、技术（免疫测定、分子诊断、血液学）、最终用途（医院、诊所） - 全球预测（2024 年- 2032 年）

由于心血管和神经系统疾病盛行率不断上升，预计 2024 年至 2032 年间，心臟病学和神经病学领域的 IVD 市场规模复合年增长率将达到 5%。根据世界卫生组织的数据，心血管疾病 (CVD) 是全球主要死亡原因，每年夺走约 1,790 万人的生命。由于心臟病和中风仍然是死亡的主要原因，对早期准确诊断工具的需求不断增加。生物标记、分子诊断和即时检测等 IVD 技术为及时检测、监测和管理这些病症提供了关键资讯。

快速的技术创新和不断增加的医疗支出也将影响市场的成长。新一代定序、数位病理学和基于人工智慧的诊断工具等新诊断平台的开发将提高测试的准确性和有效性，使其在临床环境中不可或缺。对医疗保健基础设施的投资，特别是对新兴经济体的投资，也将改善获得先进诊断服务的机会，从而扩大市场成长。

心臟病学和神经病学行业的 IVD 按产品类型、技术、最终用途和地区细分。

根据产品类型，软体和服务领域的市场份额预计到 2032 年将产生可观的收入，这有利于其准确性、效率和诊断程序的整合。先进的软体可以分析复杂的诊断资料，从而做出准确、及时的患者护理决策，同时实现程序自动化并提高效率。资料管理、远端监控和远距医疗等服务也变得越来越重要，特别是由于慢性心血管和神经系统疾病的流行。

由于对血液相关参数提供重要见解的强烈需求，血液学技术领域的心臟病学和神经病学行业的 IVD 预计将在 2024 年至 2032 年期间出现可观的增长。全血球计数 (CBC) 和凝血谱等血液学检查有助于检测贫血、凝血障碍以及可能严重影响心臟和大脑健康的疾病等状况。这些测试对于评估风险因素、检查疾病进展和评估治疗措施的有效性也很重要。

由于神经系统和心血管疾病的负担日益增加，预计亚太地区心臟病学和神经系统疾病的 IVD 行业将在 2024 年至 2032 年期间以适度的速度增长。快速的城市化和生活方式的改变导致中风、失智症和冠心病等疾病的发病率激增，进一步增加了对先进诊断解决方案的需求。该地区多个政府也大力投资卫生基础设施，并透过公共卫生措施促进早期诊断，刺激了该地区市场的成长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 心血管和神经系统疾病的盛行率不断上升
    • IVD 诊断技术的进步
    • 护理点测验的采用率不断上升
    • 日益关注新型诊断方法开发的研究
  • 产业陷阱与挑战
    • 严格的监管场景
    • 开发成本高
• 成长潜力分析
• 技术景观
• 监管环境
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 公司市占率分析
• 竞争定位矩阵
• 战略展望矩阵

第 5 章：市场估计与预测：按产品类型，2021 - 2032 年

• 主要趋势
• 仪器
• 试剂、试剂盒和消耗品
• 软体与服务

第 6 章：市场估计与预测：按技术分类，2021 - 2032 年

• 主要趋势
• 免疫测定
  • 酵素连结免疫吸附测定法 (ELISA)
  • 化学发光免疫分析 (CLIA)
  • 萤光免疫分析 (FIA)
  • 其他免疫测定
• 分子诊断
  • 聚合酶炼式反应 (PCR)
  • 杂交
  • 定序
  • 等温核酸扩增技术（INAAT）
  • 微阵列
  • 其他分子诊断
• 血液学
• 其他技术

第 7 章：市场估计与预测：按最终用途，2021 - 2032 年

• 主要趋势
• 医院和诊所
• 诊断实验室
• 其他最终用户

第 8 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 欧洲其他地区
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 沙乌地阿拉伯
  • 南非
  • 阿联酋
  • 中东和非洲其他地区

第 9 章：公司简介

• Abbott Laboratories
• Becton, Dickinson and Company
• bioMerieux S.A.
• Bio-Rad Laboratories, Inc.
• Danaher Corporation
• DiaSorin S.p.A.
• F. Hoffmann-La Roche Ltd.
• QIAGEN N.V.
• Siemens Healthineers AG
• Sysmex Corporation
• Thermo Fisher Scientific Inc.

IVD in cardiology and neurology market size is projected to record 5% CAGR between 2024 and 2032, driven by the rising prevalence of cardiovascular and neurological diseases. As per WHO, cardiovascular diseases (CVDs) are the major cause of death worldwide, claiming around 17.9 million lives every year. As heart diseases and strokes continue to be the leading causes of death, the demand for early and accurate diagnostic tools is increasing. IVD technologies, such as biomarkers, molecular diagnostics, and point-of-care testing provide critical information for the timely detection, monitoring, and management of these conditions.

Rapid technological innovations and increasing healthcare expenditures will also influence the market growth. The development of new diagnostic platforms, such as next-generation sequencing, digital pathology, and AI-based diagnostic tools will improve the accuracy and efficacy of tests, making them indispensable in clinical settings. Investments in healthcare infrastructure, specifically in emerging economies, will also improve access to advanced diagnostic services, expanding the market growth.

The IVD in cardiology and neurology industry is segmented into product type, technology, end-use and region.

Based on product type, the market share from the software & services segment is poised to generate substantial revenue by 2032, favored their accuracy, efficiency, and integration of diagnostic procedures. Advanced software enables analysis of complex diagnostic data for accurate and timely patient care decisions while automating procedures and improving efficiency. Services, such as data management, remote monitoring and telemedicine are also becoming increasingly important, especially due to the prevalence of chronic cardiovascular and neurological diseases.

IVD in cardiology and neurology industry from the hematology technology segment is slated to witness decent growth during 2024-2032, led by the strong need for providing crucial insights into blood-related parameters. Hematology tests, such as complete blood count (CBC) and coagulation profiles help detect conditions like anemia, clotting disorders, and diseases that can seriously affect heart and brain health. These tests are also important to assess risk factors, examine the progression of the disease and estimate the effectiveness of treatment measures.

Asia Pacific IVD in cardiology and neurology industry is anticipated to expand at a modest rate over 2024-2032, attributed to the increasing burden of neurological and cardiovascular diseases. Rapid urbanization and lifestyle changes have surged the incidence of diseases, such as strokes, dementia, and coronary heart disease, further increasing the demand for advanced diagnostic solutions. Multiple governments in the region are also investing significantly in health infrastructure and promoting early diagnosis through public health initiatives, stimulating the regional market growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing prevalence of cardiovascular and neurological disorders
    • 3.2.1.2 Technological advancements in IVD diagnostics
    • 3.2.1.3 Rising adoption of point of care testing
    • 3.2.1.4 Increasing focus on research for the development of novel diagnostics
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Stringent regulatory scenario
    • 3.2.2.2 High development costs
• 3.3 Growth potential analysis
• 3.4 Technological landscape
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Instruments
• 5.3 Reagents, kits, & consumables
• 5.4 Software & services

Chapter 6 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Immunoassays
  • 6.2.1 Enzyme-linked immunosorbent assay (ELISA)
  • 6.2.2 Chemiluminescence immunoassay (CLIA)
  • 6.2.3 Fluorescence immunoassay (FIA)
  • 6.2.4 Other immunoassays
• 6.3 Molecular diagnostics
  • 6.3.1 Polymerase chain reaction (PCR)
  • 6.3.2 Hybridization
  • 6.3.3 Sequencing
  • 6.3.4 Isothermal nucleic acid amplification technology (INAAT)
  • 6.3.5 Microarrays
  • 6.3.6 Other molecular diagnostics
• 6.4 Hematology
• 6.5 Other technologies

Chapter 7 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals & clinics
• 7.3 Diagnostic laboratories
• 7.4 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 South Africa
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Abbott Laboratories
• 9.2 Becton, Dickinson and Company
• 9.3 bioMerieux S.A.
• 9.4 Bio-Rad Laboratories, Inc.
• 9.5 Danaher Corporation
• 9.6 DiaSorin S.p.A.
• 9.7 F. Hoffmann-La Roche Ltd.
• 9.8 QIAGEN N.V.
• 9.9 Siemens Healthineers AG
• 9.10 Sysmex Corporation
• 9.11 Thermo Fisher Scientific Inc.